Ansofaxine hydrochloride extended release - Luye Pharma

Drug Profile

Ansofaxine hydrochloride extended release - Luye Pharma

Alternative Names: 4-Methylbenzoate desvenlafaxine hydrochloride; Desvenlafaxine prodrug; LY03005

Latest Information Update: 15 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Luye Pharma Group
  • Class Antidepressants; Benzoates; Cyclohexanols; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 23 Jan 2018 Luye Pharma has patent protection for ansofaxine in USA, Europe, China, Japan and Korea
  • 23 Jan 2018 Phase-II clinical trials in Major depressive disorder in China (PO) before January 2018
  • 23 Jan 2018 Luye Pharma completes a phase II trial in Major depressive disorder in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top